One-Time infusion aims to build cancer killers inside the body
NCT ID NCT06539338
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early study tests a new gene therapy called INT2104 in 10 adults with B-cell cancers that have come back or not responded to treatment. The therapy is given as a single IV infusion and works by instructing the body to create its own cancer-fighting T cells and natural killer cells. The main goal is to check safety, but researchers will also look for signs that the treatment is working.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BURKITT LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hospital MD Anderson
Madrid, 28033, Spain
-
Peter MacCallum Cancer Centre
Melbourne, Victoria, 3000, Australia
-
Westmead Hospital
Westmead, New South Wales, 2145, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Engineered immune cells take aim at Hard-to-Treat lymphomas
- Can a cheaper copy of a leukemia drug work just as well?
- Double-Pronged immune cells take aim at stubborn blood cancers
- New transplant recipe aims to tame Graft-Versus-Host disease
- Can a more intense chemo regimen beat aggressive lymphoma?
- New drug combo aims to make stem cell transplants safer for blood cancer patients